Hypertension in black patients: Special issues and considerations

Current Hypertension Reports

Volumn 7, Issue 4, 2005, Pages 244-248

  Nesbitt, Shawna D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; LOSARTAN; METHACHOLINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

AFRICAN AMERICAN; ETHNIC DIFFERENCE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SALT LOADING; SALT SENSITIVITY; STROKE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

EID: 24944505686     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0020-5     Document Type: Review

References (51)

1. Cappuccio FP, Micah FB, Emmett L, et al.: Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension 2004, 43:1017-1022.
2. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290:199-206.
3. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
4. Flack JM, Ferdinand KC, Nasser SA: Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens (Greenwich) 2003, 5(1 Suppl 1):5-11.
5. Flack JM, Peters R, Mehra VC, Nasser SA: Hypertension in special populations. Cardiol Clin 2002, 20:303-319.
6. Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 1996, 27(3 Pt 2):481-490.
7. Luft FC, Grim CE, Higgins JT Jr., Weinberger MH: Differences in response to sodium administration in normotensive white and black subjects. J Lab Clin Med 1977, 90:555-562.
8. Sullivan JM, Prewitt RL, Ratts TE: Sodium sensitivity in normotensive and borderline hypertensive humans. Am J Med Sci 1988, 295:370-377.
9. Madhavan S, Alderman MH: Ethnicity and the relationship of sodium intake to blood pressure. J Hypertens 1994, 12:97-103.
10. He FJ, Markandu ND, Sagnella GA, MacGregor GA: Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998, 32:820-824.
11. Wilson TW, Grim CE: Biohistory of slavery and blood pressure differences in blacks today. A hypothesis. Hypertension 1991, 17(1 Suppl):I122-I128.
12. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288(14):1723-1727.
13. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
14. Cooper RS, Kaufman JS: Race and hypertension: science and nescience. Hypertension 1998, 32:813-816.
15. Gillum RF, Mussolino ME, Madans JH: Body fat distribution and hypertension incidence in women and men. The NHANES I Epidemiologic Follow-up Study. Int J Obes Relat Metab Disord 1998, 22:127-134.
16. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998, 22:39-47.
17. Hahn RA, Heath GW, Chang MH: Cardiovascular disease risk factors and preventive practices among adults-United States, 1994: a behavioral risk factor atlas. Behavioral Risk Factor Surveillance System State Coordinators. MMWR CDC Surveill Summ 1998, 47:35-69.
18. Haffner SM, Ferrannini E, Hazuda HP, Stern MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992, 20:38-45.
19. Saad MF, Lillioja S, Nyomba BL, et al.: Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991, 324:733-739.
20. Manolio TA, Savage PJ, Burke GL, et al.: Association of fasting insulin with blood pressure and lipids in young adults. The CARDIA study. Arteriosclerosis 1990, 10:430-436.
21. Park YW, Zhu S, Palaniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003, 163:427-436.
22. Appel LJ, Champagne CM, Harsha DW, et al., for the Writing Group of the PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA 2003, 289:2083-2093.
23. Julius S, Valentini M, Palatini P: Overweight and hypertension: a 2-way street? Hypertension 2000, 35:807-813.
24. Levine JA, Eberhardt NL, Jensen MD: Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999, 283:212-214.
25. Weyer C, Pratley RE, Snitker S, et al.: Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000, 36:531-537.
26. Abate NI, Mansour YH, Tuncel M, et al.: Overweight and sympathetic overactivity in black Americans. Hypertension 2001, 38:379-383.
27. Nesbitt S, Victor RG: Pathogenesis of hypertension in African Americans. Congest Heart Fail 2004, 10:24-29.
28. Luke A, Adeyemo A, Kramer H, et al.: Association between blood pressure and resting energy expenditure independent of body size. Hypertension 2004, 43:555-560.
29. Anderson NB, Mcneilly M: Autonomic reactivity and hypertension in blacks: toward a contextual model. In Pathophysiology of Hypertension in Blacks. Edited by Fray JCS, Douglas JG. New York: Oxford Press; 1993.
30. Grubbs AL, Ergul A: A review of endothelin and hypertension in African American individuals. Ethn Dis 2001, 11:741-748.
31. Vita JA: Nitric oxide and vascular reactivity in African American patients with hypertension. J Cardiac Failure 2003, 9:S199-S204.
32. Hypertension Detection and Follow-up Program Cooperative Group: Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA 1988, 259:2113-2122.
33. Wright JT Jr, Bakris G, Greene T, et al., for the African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002, 288:2421-2431.
34. Din-Dzietham P, Nembhard WN, Collins R, Davis SK: Perceived stress following race-based discrimination at work is associated with hypertension in African-Americans. The metro Atlanta heart disease study, 1999-2001. Soc Sci Med 2004, 58:449-461.
35. Steffen PR, McNeilly M, Anderson N, Sherwood A: Effects of perceived racism and anger inhibition on ambulatory blood pressure in African Americans. Psychosom Med 2003, 65:746-750.
36. Gornick ME, Eggers PW, Reilly TW, et al.: Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 1996, 335:791-799.
37. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
38. Douglas JG, Bakris GL, Epstein M, et al., for the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks: Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003, 163:525-541.
39. Joint National Committee: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413-2446.
40. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999, 17:151-183.
41. Schwartz RS: Racial profiling in medical research. N Engl J Med 2001, 344:1392-1393.
42. Flack JM, Mensah GA, Ferrario CM: Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin 2000, 16:66-79.
43. Jamerson KA: Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. Am J Kidney Dis 2000, 36(3 Suppl 1):S24-S30.
44. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
45. He J, Whelton PK: Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999, 138(3 Pt 2):211-219.
46. Richardson AD, Piepho RW: Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther 2000, 38:75-79.
47. Cushman WC, Reda DJ, Perry HM, et al.: Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 2000, 160:825-831.
48. Saunders E, Weir MR, Kong BW, et al.: A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990, 150:1707-1713.
49. Materson BJ, Reda DJ, Williams D: Lessons from combination therapy in Veterans Affairs Studies. Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. Am J Hypertens 1996, 9(12 Pt 2):187S-191S.
50. Yancy CW, Fowler MB, Colucci WS, et al., Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001, 344:1358-1365.
51. Julius S, Alderman MH, Beevers G, et al.: Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004, 43:1047-1055.